Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 387 results found since Jan 2013.

Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: Case reports
Conclusions: It is suggested that further investigations should be performed to understand the underlying pathophysiology.
Source: Medicine - December 30, 2021 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B ‐cells due to treatment with rituximab
AbstractOver 4 million cases of Coronavirus disease 2019 (COVID ‐19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been confirmed worldwide. Up to 20% of cases develop severe disease and the fatality rate are high.[1] Little is known however on the course of the infection in immunosuppressed patients. We therefore re port the case of a patient with COVID‐19 under immunosuppression with rituximab. This 77‐year‐old woman was admitted to the hospital with a 5‐week history of unclear fever (up to 38.5°C), hypotension (80 mmHg systolic on self‐measurement), occasional mil...
Source: Arthritis and Rheumatology - May 25, 2020 Category: Rheumatology Authors: Benedict Fallet, Diego Kyburz, Ulrich A. Walker Tags: LETTER TO THE EDITOR Source Type: research

Atypical bilateral acute retinal necrosis in a coronavirus disease 2019 positive immunosuppressed patient.
CONCLUSION AND SIGNIFICANCE: To the best of our knowledge this is the first description of a case that has undergone vitreous PCR testing for COVID-19. It is interesting to note the high level of vitreous inflammation which would not be expected in an immunosuppressed state. We present a number of possible links between the SARS-CoV-2 virus and the unusual ocular presentation of bilateral VZV viral retinitis in this patient.While extra ocular VZV outbreaks have been reported with rituximab treated patients, this report should also raise the awareness of VZV related viral retinitis in DLBCL patients on rituximab chemotherap...
Source: European Journal of Ophthalmology - November 22, 2020 Category: Opthalmology Authors: Gupta A, Dixit B, Stamoulas K, Akshikar R Tags: Eur J Ophthalmol Source Type: research

Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan
ConclusionOur study suggested that the risk factors for mortality previously reported in general COVID-19 patients, including lymphocytopenia, were also effective in cancer patients. Patients who received cytotoxic chemotherapy recently or were treated with chemotherapy, which can lead to lymphocyte reduction, had poor prognosis and prolonged periods of viral shedding.
Source: International Journal of Clinical Oncology - February 20, 2021 Category: Cancer & Oncology Source Type: research

Case Report: Anti-NF186+ CIDP After Receiving the Inactivated Vaccine for Coronavirus Disease (COVID-19)
This report adds a new possible rare side effect of a COVID-19 vaccine and provides a case for the clinical effectiveness of rituximab (RTX) in patients with anti-NF186+ CIDP.
Source: Frontiers in Neurology - March 14, 2022 Category: Neurology Source Type: research

Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis
AbstractThe rapid and global spread of severe acute respiratory syndrome coronavirus 2, a viral pathogen responsible for the development of the “coronavirus disease of 2019” (COVID-19), has developed into an unprecedented health crisis with considerable case fatality rate. Patients with comorbidities are considered to be at higher risk for severe disease with acute respiratory failure, intensive care unit admission, and/or death. Partic ular vigilance has been warranted regarding the continuation of immunosuppressive treatments since viral clearing may be hampered in such cases. In contrast, it has also been hypothesiz...
Source: Neurological Sciences - June 19, 2020 Category: Neurology Source Type: research

Risk of severe coronavirus infection (COVID-19) in patients with inflammatory rheumatic diseases
CONCLUSION: Patients with IRD, especially autoimmune diseases and patients treated with rituximab, may be at higher risk of severe pneumonia due to SARS-Cov 2, compared to the general population. More studies are needed to analyze this association further in order to help managing these patients during the pandemic.PMID:33722949 | DOI:10.3899/jrheum.200755
Source: J Rheumatol - March 16, 2021 Category: Rheumatology Authors: Javier Bachiller-Corral Alina Boteanu Maria Jesus Garcia-Villanueva Carlos de la Puente Marcelino Revenga M Consuelo Diaz-Miguel Ana Rodriguez-Garcia Jose Luis Morell-Hita Marta Valero Carmen Larena Maria Blazquez-Ca ñamero Carlos A Guillen-Astete Sandra Source Type: research